Browse News
Filter News
Found 808,586 articles
-
Cerevel Therapeutics on Thursday reported positive data from its Phase III TEMPO-3 trial, showing that tavapadon can significantly improve symptom control in patients with Parkinson’s disease.
-
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market
4/18/2024
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly. -
Nearly all doses of Eli Lilly’s highly popular weight-loss drug Zepbound and type 2 diabetes medication Mounjaro will have limited availability through the second quarter of 2024, according to the regulator.
-
Data from the Phase III OCARINA II study shows the subcutaneous version of Ocrevus achieved near-complete suppression of relapses and brain lesions in relapsing or primary progressive multiple sclerosis.
-
Fierce competition. Thin pipelines. Patent cliffs. The stakes are sky-high for pharmaceutical companies and investors alike.
-
The first Bioversity cohort includes several graduates placed at Massachusetts life sciences companies.
-
On the heels of a late-stage victory for its antipsychotic drug Caplyta in patients with major depressive disorder, Intra-Cellular Therapies is now offering 6.8 million shares at $73 a piece.
-
Teva Pharmaceuticals and Alvotech got the FDA’s greenlight for their biosimilar to Johnson & Johnson’s blockbuster Stelara, which will launch in the U.S. in February 2025.
-
How to Deal With Layoff-Related Stress
4/18/2024
Employees worried about layoffs can practice self-care, use employer resources and contact a mental health professional, if needed. -
Plus, what to expect in a phone screen and how to handle an impending layoff.
-
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
4/18/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
-
Form Bio Establishes Scientific Advisory Board, Comprised of Renowned Experts in Cell and Gene Therapy, for Advancing AI-Driven Therapies
4/18/2024
Form Bio today announced the creation of a new Scientific Advisory Board (SAB).
-
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
4/18/2024
Anixa Biosciences, Inc today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 18, 2024
4/18/2024
Schrödinger, Inc. today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees.
-
BiomX Announces the Appointment of Susan Blum to its Board of Directors
4/18/2024
BiomX Inc. today announced the appointment of Susan Blum to its Board of Directors.
-
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
4/18/2024
Immutep Limited today announces it has entered into an agreement with the Centre for Human Drug Research (CHDR), a world-class institute in Leiden, the Netherlands specializing in cutting-edge early-stage clinical drug research, to perform a first-in-human clinical study of IMP761.
-
GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembrolizumab)
4/18/2024
GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics, today announced that it has entered into a clinical collaboration and supply agreement with Merck (known as MSD outside the US and Canada).
-
Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
4/18/2024
Provectus Biopharmaceuticals, Inc. today announced that data from preclinical research by the University of Calgary on oral administration of Provectus’s pharmaceutical-grade rose bengal for the treatments of solid tumor cancers were published in the open access journal of oncology Cancers.
-
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
4/18/2024
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces receipt of clearance from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial with a seasonal COVID-19 booster vaccine.
-
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
4/18/2024
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML.